Home
The War on Cancer
Cancer A – Z
Drug Approvals 2017
Articles
Conference Coverage
Editorial
Eric Rosenthal Reports
Expert Interview
Latest Articles
Publications
News
The Onco’Zine Brief
The Onco’Zine Brief Episodes
Upcoming Programs | Shows
How to Support The Onco’Zine Brief
Underwriting
The Onco’Zine Brief on PRX
The Onco’Zine Brief on Spreaker
Programs | Shows
Oncology Directory
Join Today
Event Agenda
Video
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
About
Advertise
Advisory Board
Contact Us
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Onco'Zine
Home
The War on Cancer
Cancer A – Z
Drug Approvals 2017
Articles
Conference Coverage
Editorial
Eric Rosenthal Reports
Expert Interview
Latest Articles
Publications
News
The Onco’Zine Brief
The Onco’Zine Brief Episodes
Upcoming Programs | Shows
How to Support The Onco’Zine Brief
Underwriting
The Onco’Zine Brief on PRX
The Onco’Zine Brief on Spreaker
Programs | Shows
Oncology Directory
Join Today
Event Agenda
Video
Home
Tags
AML
Tag: AML
A Compound Being Developed to Treat an Eye Disease may also...
Peter Hofland, Ph.D
-
January 2, 2019
Daiichi Sankyo Initiates Phase I Study to Evaluate the Combination Quizartinib...
Peter Hofland, Ph.D
-
December 20, 2018
Gilteritinib Available for Prescription in the United States for Adults with...
Peter Hofland, Ph.D
-
December 11, 2018
Glasdegib Approved in Newly-Diagnosed AML Patients for Whom Intensive Chemotherapy is...
Peter Hofland, Ph.D
-
November 24, 2018
FDA Grants Accelerated Approval for Venetoclax in Newly-Diagnosed Acute Myeloid Leukemia...
Peter Hofland, Ph.D
-
November 24, 2018
Anti-Leukemic Activity and Safety Data for Gilteritinib in Relapsed
Peter Hofland, Ph.D
-
June 23, 2017
First Patient with Untreated High-risk Acute Myeloid Leukemia Enrolled in Phase...
Editorial Team
-
December 26, 2012
LATEST
ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma
Editorial Team
-
December 8, 2019
ASH 2019: Second-gen CAR T-Cell Therapy Overcome Resistance, Reduce Toxicity and Simplify Treatment
Peter Hofland, Ph.D
-
December 8, 2019
Addressing Disparities in Cancer: Factors Influencing Care, Access and Outcomes
Peter Hofland, Ph.D
-
December 8, 2019
